Opioid Use Disorder
Review sets magnitudes for effective contingency management in substance use disorders
Contingency management interventions for stimulant and opioid use disorders should offer $128 per week for vouchers or $55 per week in prizes over 12 weeks or longer to be effective, according to data published in JAMA Psychiatry.
Youth OD deaths involving only synthetic opioids rose 168% in 5 years
Opioid overdose deaths continued to rise among adolescents and young adults during a recent 5-year period, and synthetic opioids alone are becoming the predominant cause, according to findings published in Pediatrics.
Buprenorphine during pregnancy improves outcomes for mothers, babies
HONOLULU — Buprenorphine treatment during pregnancy improved perinatal outcomes for women with opioid use disorder and their babies, compared with no treatment, according to a new study.
PAS 2025 features ‘most robust and diverse program to date’
HONOLULU — More than 8,500 physicians are attending PAS 2025 — the largest turnout at the annual pediatrics conference since 2018, according to program chair Daniel Rauch, MD, FAAP, SFHM.
Street medicine improves HIV care among people who inject drugs
SAN FRANCISCO — The use of mobile health care units that distribute ART and PrEP medications increased uptake among people who inject drugs, a population at greater risk for acquiring HIV, according to a study.
Nonfatal fentanyl exposures increase nearly 1,200% among youth
Nonfatal fentanyl exposures increased nearly 1,200% among children and adolescents from 2015 to 2023, according to findings published in The American Journal of Drug and Alcohol Abuse.
FDA approves rapid initiation of Sublocade for opioid use disorder
The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation for opioid use disorder and speed up availability of treatment, according to a press release from the manufacturer.
Barriers persist to accessing substance use disorder treatment despite greater need
Although the prevalence of substance use disorder increased during the COVID-19 pandemic, the receipt of treatment declined before rebounding, according to a research letter published in JAMA Network Open.
Use of genetic variants to predict opioid use disorder risk may lead to inaccurate results
Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA Network Open.
Mindfulness treatment program reduces cravings in those with opioid addiction
An online-based mindfulness treatment program significantly reduced opioid craving among participants with opioid use disorder results from a randomized clinical trial published in JAMA Network Open showed.